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Abstract
Human sarcoma cell populations maintained in culture reflect to the native tumor cells better if the culture retains those
nonmalignant cells that comprised the tumor’s microenvironment in vivo [Hu M, et al. Characterization of 11 human
sarcoma cell strains. Cancer 2002; 95: 1569–76] and thus provide paracrine growth factors and protection from apoptotic
death to the tumor cells. Whereas sarcoma cell cultures obtained through meticulous efforts aimed at the elimination of all
non-malignant cells of the tumor’s original microenvironment consist of subpopulations of tumor cells growing exclusively
with the support of their own autocrine growth loops [Sinkovics JG, et al. Growth of human tumor cells in established
cultures. In: Busch H, ed. Methods in Cancer Research. Vol 14. New York: Academic Press, 1978; 243–323].
It has been some 30 years since that, at the Section of
Clinical Tumor Virology and Immunology,
Department of Medicine, The University of Texas
M.D. Anderson Hospital, we established over 50
human tumor cell lines,
l amongthem 25 deriving
from sarcomas.
One purpose of the study was a search for causative
retroviruses, since from the chicken through mice up
to some simian species causative sarcoma viruses
were isolated and identified. Filtered supernatant
fluids of human sarcoma cell cultures occasionally
caused ‘antigenic conversion’ (as shown by immuno-
fluorescence stains) and ‘focus formation’ in cultures
of human embryonic fibroblasts.
2 These phenomena
could not be propagated by passages and yielded no
human sarcoma viral isolates, even though transmis-
sion EM pictures showed rare retroviral particles in
some of these cells.
3 Some xenotropic murine retro-
viral particles showed up in cultured human sarcoma
cells xenografted into nude mice.
1 Another purpose
of the study was to test autologous and allogeneic
patient lymphocytes for cytotoxicity against cultured
sarcoma cells and correlate these reactions with the
clinical course of the patients.
4,5 Some spectacular
interaction between sarcoma cells and lymphocytes
occurred and were photographed. Allogeneic large
lymphocytes with granular cytoplasm lysed sarcoma
cells; smaller autologous lymphocytes with thinner
rim of cytoplasm and compact nucleus caused
clumpingin the nuclei of sarcoma cells.
6–8 These
purely morphological observations gainedtheirexpla-
nationslaterwhenNKcellsandtheirderivatives(LAK
cells) with their receptors recognizing malignantly
transformed cells (KIRs; NKp30,44,46; NKG2D)
and subtypes of immune T cells (TIL) were
separated; and perforins of lymphocyte origin and
death ligands and their receptors (TNFa;F a s L !
FasR CD95) inducingextrinsic apoptosis were dis-
covered elsewhere. Furthermore nuclear clumping
and death of the lymphocytes attackingsarcoma cells
also occurred: the ‘counterattack on lymphocytes’,
while sarcoma cells remained intact
8,9 (Fig. 1); these
pictures were taken longbefore the discovery of the
Fas system. A third and main purpose of these studies
was the preparation of ‘viral oncolysates’ from some
of these cell lines for active tumor-specific immu-
notherapy against sarcomas
10 and melanoma.
11,12
Our work as reported biannually in the institu-
tional Research Report from 1960 to 1978 preceded
the discovery of oncogenes whereby a retrovirus
transduces a cellular protooncogene (for example
c-myc,c - sis,c - src, etc.) and thus gains oncogenicity;
13
and it was carried out in the absence of the as yet
undiscovered monoclonal antibodies
14 for lympho-
cyte subtyping. Decades have since gone by and we
still do not have an established human sarcoma
vaccine to prevent potsurgical relapses and we do not
effectively utilize immune lymphocytes for adoptive
immunotherapy of metastatic disease.
We now know that our aim at establishinghuman
tumor cell lines was misdirected. When we forcefully
and with great efforts separated tumor cells from
normal connective tissue cells that accompanied
them and changed media diligently, even on week-
ends, we deprived our cultures of the as yet undis-
covered paracrine growth factors and thus selected
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growing with the support of their own autocrine
growth loops.
It was especially difficult to establish cell lines from
classical pre-AIDS Kaposi’s sarcoma (KS) tumors:
we continued to refresh the media of their primary
cultures sometimes daily and did not use ‘condi-
tioned media’. In addition to herpesviruses (CMV;
EBV in the B-lineage lymphocytes infiltrating the
tumor; and now HHV-8), KS cells occasionally
displayed buddingretrovirus particles
15,16 (Fig. 2).
We are now promotinga new workinghypothesis
that a retroviral dsDNA provirus deprived of env
gene (but occasionally capable of acquiring one)
exists in these cells inserted next to the int-bFGF
gene family, which is thus transactivated and
amplified to encode bFGF. When excess bFGF
ligands are released and captured by their receptors
Fig. 1. (a) Allogeneic large lymphocytes lyse the cytoplasm of two sarcoma cells. (b) Two autologous lymphocytes kill two melanoma
cells by causing nuclear clumping. (c) Autologous lymphocytes attacking fibrosarcoma cell undergo nuclear clumping and die while
sarcoma cell survives. J.G. Sinkovics, M.D. Anderson Hospital, Houston TX (1972–1974).
Fig. 2. Kaposi sarcoma cell with budding retroviral particles that failed to react with commercial kits aimed at HTLV-I or HIV-1
structural proteins. F. Gyorkeyy and J.G. Sinkovics, VA Medical Center, Houston TX, 1983 (unpublished).
76 J. G. Sinkovicsas expressed by the same cells, an autocrine growth
loop is established.
The recent outstandingreport
17 from the same
institution recognizes the interaction whereby sub-
verted stromal cells serve the tumor cells with growth
factors of paracrine origin. This is a highly general-
ized phenomenon
12 and it is applicable to many
tumors other than sarcomas. For example, certain
melanoma cells use the Fas ligand (L) as an
autocrine-paracrine growth factor;
18 neuroblastoma
cells are driven to grow by TNFa;
19 lymphoma cells
armed with FasL kill host immune T cells;
20 and
CLL cells are protected from apoptosis by IFNg or
by stromal cell-derived factor-1 (SDF-1) released
from subverted fibroblast-like cells of the host.
20
While the c-sis-product PDGF and molecular
mediators of neoangiogenesis (bFGF; VEGF and
their receptors) are well recognized growth factors
for sarcoma cells, SDF-1 has not as yet received the
attention it deserves.
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